Phase 1b/2 Study of Surufatinib in Combination with Docetaxel As Second-Line Treatment of Advanced Driver-Gene Negative Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要